In the latest trading session, 0.95 million Prelude Therapeutics Inc (NASDAQ:PRLD) shares changed hands as the company’s beta touched 1.40. With the company’s most recent per share price at $1.36 changing hands around $0.06 or 4.62% at last look, the market valuation stands at $109.58M. PRLD’s current price is a discount, trading about -400.0% off its 52-week high of $6.80. The share price had its 52-week low at $0.80, which suggests the last value was 41.18% up since then. When we look at Prelude Therapeutics Inc’s average trading volume, we note the 10-day average is 1.02 million shares, with the 3-month average coming to 425.48K.
Analysts gave the Prelude Therapeutics Inc (PRLD) stock a consensus recommendation rating of Sell, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 2 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PRLD as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Prelude Therapeutics Inc’s EPS for the current quarter is expected to be -0.47.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prelude Therapeutics Inc (NASDAQ:PRLD) trade information
Instantly PRLD is in green as seen in intraday trades today. With action 51.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -68.15%, with the 5-day performance at 51.84% in the green. However, in the 30-day time frame, Prelude Therapeutics Inc (NASDAQ:PRLD) is 40.61% up. Looking at the short shares, we see there were 3.06 million shares sold at short interest cover period of 7.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 72.8% from its recent market value. According to analyst projections, PRLD’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -267.65% plunge from its current level, while the stock would need to soar -267.65% for it to hit the projected low.
Prelude Therapeutics Inc (PRLD) estimates and forecasts
Data shows that the Prelude Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -64.12% over the past 6 months, a 10.40% in annual growth rate that is considerably lower than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.14%. The 2024 estimates are for Prelude Therapeutics Inc earnings to increase by 12.13%, but the outlook for the next 5-year period is at 30.10% per year.
PRLD Dividends
Prelude Therapeutics Inc is expected to release its next quarterly earnings report in January.
Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.36% of Prelude Therapeutics Inc shares while 84.98% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.76%. There are 84.98% institutions holding the Prelude Therapeutics Inc stock share, with ORBIMED ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 14.4043% of the shares, roughly 10.91 million PRLD shares worth $41.56 million.
BAKER BROS. ADVISORS LP holds the second largest percentage of outstanding shares, with 13.3673% or 10.12 million shares worth $38.57 million as of 2024-06-30.
